Alaunos Therapeutics names Dale Hogue as Interim CEO, effective Jan 20, 2024

Alaunos Therapeutics, Inc.

Dale Curtis Hogue, Jr. appointed Interim CEO; will continue serving on the Board.
Hogue founded family office Dune Lake Capital; spent 8 years as senior analyst at Discovery Capital Management.
Employment terms: $250,000 base salary; option to buy 600,000 shares at $0.12.
Option vests 50,000 shares monthly over 12 months subject to continued employment; unvested shares forfeited.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Dale Curtis Hogue, Jr.

Interim Chief Executive Officer

TCRT · Alaunos Therapeutics, Inc.

Effective: 2024-01-20
Filed: January 22, 2024, 6:59 PM ET

On January 20, 2024, the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) appointed Dale Curtis Hogue, Jr. as Interim Chief Executive Officer of the Company, effective January 20, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dale Curtis Hogue, Jr. was appointed as Interim Chief Executive Officer at Alaunos Therapeutics, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

On January 20, 2024, the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) appointed Dale Curtis Hogue, Jr. as Interim Chief Executive Officer of the Company, effective January 20, 2024.

View on SEC.gov

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-012201

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.